ARS Pharmaceuticals, Inc. (NASDAQ:SPRY – Get Rating) – Research analysts at SVB Leerink increased their FY2026 earnings estimates for shares of ARS Pharmaceuticals in a report released on Friday, January 27th. SVB Leerink analyst R. Ruiz now forecasts that the company will post earnings per share of $0.50 for the year, up from their prior estimate of $0.45. SVB Leerink currently has a "Outperform" rating and a $14.00 target price on the stock. The consensus estimate for ARS Pharmaceuticals' current full-year earnings is ($0.57) per share.

ARS Pharmaceuticals (NASDAQ:SPRY – Get Rating) last announced its quarterly earnings data on Wednesday, November 2nd. The company reported ($0.50) earnings per share for the quarter.

ARS Pharmaceuticals Trading Down 1.3 %

SPRY opened at $6.32 on Monday. ARS Pharmaceuticals has a 12 month low of $2.80 and a 12 month high of $9.17. The firm has a market cap of $227.90 million, a PE ratio of -2.61 and a beta of 0.20. The firm has a 50 day simple moving average of $7.30.

Insider Buying and Selling at ARS Pharmaceuticals

In other ARS Pharmaceuticals news, CFO Kathleen D. Scott purchased 8,250 shares of the business's stock in a transaction dated Tuesday, November 29th. The stock was bought at an average cost of $6.24 per share, for a total transaction of $51,480.00. Following the completion of the acquisition, the chief financial officer now directly owns 8,250 shares in the company, valued at $51,480. The purchase was disclosed in a filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 34.40% of the company's stock.

ARS Pharmaceuticals Company Profile

(Get Rating)

ARS Pharmaceuticals, Inc develops ARS-1, a novel intranasal epinephrine spray with absorption technology for patients and their families at-risk of severe allergic reactions to food, medications, and insect bites. Its product includes Neffy, a low-dose intranasal epinephrine nasal spray. The company was incorporated in 2015 and is based in San Diego, California.

Recommended Stories

• Get a free copy of the StockNews.com research report on ARS Pharmaceuticals (SPRY)
• Can Yext A.I. Search Platform Drive Growth in 2023?
• Cassava Sciences Stock Undervalued with Its $124 Price Target?
• Constellation Brands: Are Consumers Trading Down for Rail Drinks?
• Capital One Stock: Will Subprime Borrowers Spoil the Rally?
• MarketBeat Week in Review – 1/23- 1/27

Receive News & Ratings for ARS Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ARS Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.